We should implement new reimbursement scheme that does away with pay-per-use pricing and instead pays a license fee for access to hospital based antibiotics targeting resistant organisms. This pull incentive will guarantee a market and promote stewardship.
“The low-hanging fruit has been plucked,” says Amanda Jezek, IDSA’s senior vice president for public policy and government relations, on the uncertain future of #antibiotic R&D. #DISARMSuperbugs
Antibiotics Developers Seek a Cure for Industry Ills via ⁦⁩ ⁦⁩ #AMR
The cost of developing new antibiotics is rising, while cash-strapped hospitals are reluctant to splash out on higher-priced infection-fighting medicines via